These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12057035)

  • 1. Serotonin syndrome - 'potential' role of the CYP2D6 genetic polymorphism in Asians.
    Kaneda Y; Kawamura I; Fujii A; Ohmori T
    Int J Neuropsychopharmacol; 2002 Mar; 5(1):105-6. PubMed ID: 12057035
    [No Abstract]   [Full Text] [Related]  

  • 2. Delirium associated with paroxetine in an elderly depressive patient: a case report.
    Wakeno M; Okugawa G; Takekita Y; Kato M; Fukuda T; Yamashita M; Hosoi Y; Azuma J; Kinoshita T
    Pharmacopsychiatry; 2007 Sep; 40(5):199-200. PubMed ID: 17874351
    [No Abstract]   [Full Text] [Related]  

  • 3. Recognition and treatment of serotonin syndrome.
    Frank C
    Can Fam Physician; 2008 Jul; 54(7):988-92. PubMed ID: 18625822
    [No Abstract]   [Full Text] [Related]  

  • 4. Serotonin toxicity in a CYP2D6 poor metabolizer, initially diagnosed as a drug-resistant major depression.
    Gressier F; Ellul P; Dutech C; Ait Tayeb AEK; Monfort J; Corruble E; Becquemont L; Hardy P; Verstuyft C
    Am J Psychiatry; 2014 Aug; 171(8):890. PubMed ID: 25082493
    [No Abstract]   [Full Text] [Related]  

  • 5. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
    Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
    Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of combined treatment with lithium and paroxetine in patients with bipolar disorder and depression.
    Fagiolini A; Buysse DJ; Frank E; Houck PR; Luther JF; Kupfer DJ
    J Clin Psychopharmacol; 2001 Oct; 21(5):474-8. PubMed ID: 11593071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between CYP 2D6 metabolic status and sexual dysfunction in paroxetine treatment.
    Zourková A; Hadasová E
    J Sex Marital Ther; 2002; 28(5):451-61. PubMed ID: 12378847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Life-threatening serotonin syndrome in a patient with chronic heart failure and CYP2D6*1/*5.
    Sato A; Okura Y; Minagawa S; Ohno Y; Fujita S; Kondo D; Hayashi M; Komura S; Kato K; Hanawa H; Kodama M; Aizawa Y
    Mayo Clin Proc; 2004 Nov; 79(11):1444-8. PubMed ID: 15544025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
    Hicks JK; Bishop JR; Sangkuhl K; Müller DJ; Ji Y; Leckband SG; Leeder JS; Graham RL; Chiulli DL; LLerena A; Skaar TC; Scott SA; Stingl JC; Klein TE; Caudle KE; Gaedigk A;
    Clin Pharmacol Ther; 2015 Aug; 98(2):127-34. PubMed ID: 25974703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More cases of paroxetine withdrawal syndrome.
    Pacheco L; Malo P; Aragues E; Etxebeste M
    Br J Psychiatry; 1996 Sep; 169(3):384. PubMed ID: 8879736
    [No Abstract]   [Full Text] [Related]  

  • 11. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?
    Zembutsu H; Sasa M; Kiyotani K; Mushiroda T; Nakamura Y
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):185-93. PubMed ID: 21342038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyponatraemia associated with the use of a selective serotonin-reuptake inhibitor in an older patient.
    Schouten WE; Sepers JM
    Age Ageing; 2001 Jan; 30(1):94. PubMed ID: 11322690
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient.
    Hébant B; Guillaume M; Desbordes M; Gaillon G; Maltête D; Lefaucheur R
    Rev Neurol (Paris); 2016 Dec; 172(12):788-789. PubMed ID: 27838092
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe sleepiness and excess sleep duration induced by paroxetine treatment is a beneficial pharmacological effect, not an adverse reaction.
    Murata Y; Kamishioiri Y; Tanaka K; Sugimoto H; Sakamoto S; Kobayashi D; Mine K
    J Affect Disord; 2013 Sep; 150(3):1209-12. PubMed ID: 23809402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics in pharmacokinetics?
    Hartter S
    Am J Psychiatry; 2004 Jul; 161(7):1308-9; author reply 1309. PubMed ID: 15229072
    [No Abstract]   [Full Text] [Related]  

  • 16. Low serum concentrations of paroxetine in CYP2D6 ultrarapid metabolizers.
    Güzey C; Spigset O
    J Clin Psychopharmacol; 2006 Apr; 26(2):211-2. PubMed ID: 16633156
    [No Abstract]   [Full Text] [Related]  

  • 17. [The serotonin syndrome].
    Kozian R
    Psychiatr Prax; 2005 Oct; 32(7):367-9. PubMed ID: 16220422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.
    Nishimura M; Ueda M; Saruwatari J; Nakashima H; Ogusu N; Aoki A; Tsuchimine S; Matsuda K; Iwashita K; Ono T; Oniki K; Shimoda K; Yasui-Furukori N
    Pharmacogenet Genomics; 2016 Sep; 26(9):403-13. PubMed ID: 27187662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paroxetine-related tremor.
    Lai H; Tolat R
    Geriatrics; 2005 Jul; 60(7):18-20. PubMed ID: 16026177
    [No Abstract]   [Full Text] [Related]  

  • 20. Withdrawal syndromes after paroxetine and sertraline discontinuation.
    Fava GA; Grandi S
    J Clin Psychopharmacol; 1995 Oct; 15(5):374-5. PubMed ID: 8830071
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.